Gastroenterology

Gastroenterology

Volume 112, Issue 4, April 1997, Pages 1103-1113
Gastroenterology

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer

https://doi.org/10.1016/S0016-5085(97)70120-3Get rights and content

Abstract

BACKGROUND & AIMS: HER-2/neu oncogene encodes a transmembrane tyrosine kinase receptor that is amplified and/or overexpressed predominantly in adenocarcinomas. This phenomenon has been most intensively studied in breast carcinoma where its amplification and overexpression correlate with the overall course of disease and poor prognosis. This study was designed to investigate HER-2/neu gene expression in benign and malignant colorectal lesions and to evaluate its prognostic importance in colorectal cancer. METHODS: Two hundred twenty-one samples of normal colon, benign lesions, and colorectal adenocarcinomas were studied for expression of HER-2/neu oncoprotein. Immunohistochemical staining of formalin-fixed, paraffin-embedded tissue sections of primary tumor and lymph nodes was performed. Immunoprecipitation followed by Western blotting of freshly frozen samples of the same tumors were also performed. RESULTS: Normal colon mucosa, benign lesions, and adenocarcinomas clearly differed in the expression levels and histological distribution of p185(HER-2/neu). Normal mucosa was mostly negative, but significant number of benign lesions and adenocarcinomas overexpressed HER-2/neu protein. Adenocarcinomas were significantly more positive than benign lesions. The results show significant correlation with the epithelial abnormality degree and clinical parameters including Dukes' classification and relapse-free and postoperative survival period. CONCLUSIONS: The p185(HER-2/neu) rate expression could serve as an independent prognostic factor in patients with p185(HER-2/neu)-positive colorectal malignancies. (Gastroenterology 1997 Apr;112(4):1103-13)

References (0)

Cited by (201)

  • HER2 in Colorectal Carcinoma: Are We There yet?

    2020, Surgical Pathology Clinics
    Citation Excerpt :

    The overall prognostic significance of ERBB2 amplification in CRC is uncertain. Although early studies reported an association with worse prognosis, these studies considered cytoplasmic expression of ERBB2 as a criterion for positivity.17,44 More recent studies that evaluated only membranous ERBB2 expression have not demonstrated a clear association with prognosis (see Table 1), although a trend toward worse overall survival was identified in one of the largest published studies to date.39

  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

    2018, Annals of Oncology
    Citation Excerpt :

    The prognostic role of HER2 in CRC remains uncertain. A negative prognostic impact of HER2 overexpression was proposed in earlier studies [27, 28], but more recent trials have found no association between HER2 amplification and outcome (Table 1 [16, 19, 21, 22, 25]). However, in one of the largest study cohorts examined (1645 patients with stages I–IV CRC), a trend toward worse OS was reported for the 26 (1.6%) patients with HER2-positive disease compared with those with HER2-negative disease [18].

View all citing articles on Scopus
View full text